USP28-NMMHC IIA Axis Drives Sepsis-Induced Organ Injury
The study identifies a potential molecular target for preventing endothelial necroptosis during septic events.
Updated on Oct. 15, 2026 in Life Sciences
Researchers have identified that the USP28-NMMHC IIA protein axis drives endothelial necroptosis, or cell death, in septic mice. This study characterizes a mechanism where USP28 stabilizes NMMHC IIA, ultimately exacerbating multi-organ injury during sepsis.
Why it matters
This research reveals a specific molecular pathway that contributes to organ failure in sepsis, potentially identifying a new target for therapeutic intervention. The findings clarify the feedback loop between IFNAR1 signaling and USP28 expression that fuels tissue damage.
USP28 stabilizes NMMHC IIA by removing K48-linked ubiquitination at the K1413 site. This stabilization allows for increased plasma membrane trafficking of IFNAR1, which strengthens STAT1-mediated necroptosis signals.
The players
USP28
A deubiquitinase enzyme that functions in this study to stabilize NMMHC IIA and drive pathological cell death.
NMMHC IIA
A protein whose stability is regulated by USP28 to facilitate the trafficking of interferon receptors.
The details
In the presence of sepsis, endothelial cells—the cells lining the blood vessels—undergo a form of programmed cell death called necroptosis. The protein USP28 acts as a molecular stabilizer for NMMHC IIA, a non-muscle myosin heavy chain protein, by preventing its degradation. Once stabilized, NMMHC IIA facilitates the movement of IFNAR1, an interferon receptor, to the cell surface, where it triggers STAT1 signaling. This process creates a positive feedback loop, as STAT1 subsequently increases the production of USP28, further accelerating tissue damage.
Timeline
October 15, 2026: The research findings were published.
The Tech Race
This study advances the field by mapping the precise USP28-NMMHC IIA feedback loop within the broader effort to understand and treat sepsis-induced organ failure. It distinguishes itself from general anti-inflammatory approaches by highlighting a specific protein-axis target for potential inhibition.
This discovery provides a potential mechanism for future therapeutic development to prevent multi-organ injury in sepsis patients. Because the research is currently limited to murine models, clinical applications remain a long-term goal for medical science.
The takeaway
The study identifies the USP28-NMMHC IIA axis as a critical driver of organ injury during sepsis. Researchers and clinicians should monitor future drug development efforts targeting the USP28-IFNAR1 pathway for potential use in intensive care settings.
Further reading
For broader developments in this field, explore our latest reports in Life Sciences.
More information
Read the full study in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
